PGDx, MolecularMD Ink Co-Marketing Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.

Further financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.